Last reviewed · How we verify

Sustained ventricular tachycardia — Treatment Landscape & Competitive Intelligence

Sustained ventricular tachycardia (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Sustained ventricular tachycardia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Norpace Cr Disopyramide Phosphate Pfizer High Risk QT Prolonging Agents G protein-activated inward rectifier potassium channel 4 1977-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 1 drug in Sustained ventricular tachycardia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Sustained ventricular tachycardia:

Cite this brief

Drug Landscape (2026). Sustained ventricular tachycardia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sustained-ventricular-tachycardia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing